Ascendis Pharma A/S

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-13 pm EDT			5-day change	1st Jan Change
119.22 ^USD	+4.75%		+0.06%	-5.34%

Sep. 13	European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit	MT
Sep. 13	Ascendis Says Initial Data Shows Anti-Tumor Activity in Phase 1/2 Platinum-Resistant Ovarian Cancer Trial	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Ascendis Pharma A/S

European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit	Sep. 13	MT
Ascendis Says Initial Data Shows Anti-Tumor Activity in Phase 1/2 Platinum-Resistant Ovarian Cancer Trial	Sep. 13	MT
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024	Sep. 13	CI
Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment	Sep. 12	MT
Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.	Sep. 11	DJ
Oppenheimer Upgrades Ascendis Pharma A/S to Outperform From Perform, $180 Price Target	Sep. 05	MT
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	Sep. 04	MT
Sector Update: Health Care Stocks Fall Premarket Wednesday	Sep. 04	MT
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement	Sep. 03	MT
Ascendis Pharma Q2 Loss Narrows, Sales Slump -- Shares Plunge After Hours	Sep. 03	MT
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q2 Revenue EUR36M	Sep. 03	MT
Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Sep. 03	CI
Transcript : Ascendis Pharma A/S, Q2 2024 Earnings Call, Sep 03, 2024	Sep. 03
Evercore ISI Raises Price Target on Ascendis Pharma to $200 From $191, Keeps Outperform Rating	Aug. 26	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Aug. 22	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Aug. 13	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	Aug. 12	MT
Sector Update: Health Care Stocks Flat to Higher Pre-bell Monday	Aug. 12	MT
Ascendis Pharma Shares Climb on U.S. FDA Approval for Hypoparathyroidism Treatment Yorvipath	Aug. 12	DJ
Sector Update: Health Care	Aug. 12	MT
Transcript : Ascendis Pharma A/S - Special Call	Aug. 12
Ascendis Pharma Gets U.S. FDA Approval for Hypoparathyroidism Treatment	Aug. 12	DJ
Ascendis Pharma Gets US FDA Approval of Hypoparathyroidism Therapy	Aug. 12	MT
FDA approves Ascendis Pharma's hormone disorder therapy	Aug. 12	RE
Ascendis Pharma A/S Announces Food & Drug Administration Approves Yorvipath® (Palopegteriparatide; Developed as Transcon Pth) for the Treatment of Hypoparathyroidism in Adults	Aug. 12	CI

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

879

Sector

Biotechnology & Medical Research

Calendar

2024-11-05 - Q3 2024 Earnings Release (Projected)

More about the company